In the present study, all the 18 metabolites hold the promise as alternative diagnostic tools for discrimination of PCa from BPH at the gray zone of PSA 4–10 ng/ml (all AUC > 0.80). Here, KLK3 is linked to benign prostatic hyperplasia.